PM Modi congratulated India for DCGI granting approval to Serum Institute of India vaccines and Bharat Biotech is speeding the path to a COVID-free country.
The Drug Controller General of India (DCGI) approved Oxford COVID-19 vaccine Covishield, created by the Serum Institute, and natively developed Bharat Biotech covaxin for restricted emergency use in the region. “Vaccines of the Serum Institute of India and Bharat Biotech are granted permission for restricted use in emergency situations,” said DCGI Dr. VG Somani today.
After a thorough study, the Central Drugs Quality Control Organisation (CDSCO) has agreed to adopt the recommendations of the Expert Committee, and M/s Serum and M/s Bharat Biotech vaccines are now licenced for restricted use in emergency situations,” Somani told reporters.
Covishield and Covaxin have to be administered in two doses and can be stored at 2-8 degrees Celsius. The DCGI has also granted permission to Cadila healthcare for phase 3 clinical trial in India.
The Prime Minister hailed the move and tweeted “This shows the eagerness of our scientific community to fulfil the dream of Aatmanirbhar Bharat, whose root is care and compassion,” he said, congratulating the country, scientists and innovators.
The Prime Minister expressed his appreciation to the physicians, medical professionals, scientists, police officers, sanitation workers and all ‘Corona Fighters’ for the excellent work they have performed in adverse conditions, and said that the country will remain forever grateful to them for saving many lives.
“A decisive turning point in order to reinforce a vigorous battle! DCGI’s approval of the @SerumInstIndia and @BharatBiotech vaccines accelerates the road to a safe and COVID-free country. Ok, congratulations to India. Congratulations to our hard-working scientists and innovators,” he posted.
Reacting to the announcement, SII Chief Adar Poonawalla said, “Happy New Year, everyone! https://twitter.com/adarpoonawalla/status/1345605880381784067?s=20
